{"id":"bilhvax-vaccine-sh28gst","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses the Sh28GST antigen, a glutathione S-transferase fusion protein derived from S. haematobium, to stimulate both cellular and humoral immunity against the parasite. This approach aims to reduce parasite burden and associated morbidity in infected individuals by enhancing the host's natural immune defenses against schistosomiasis.","oneSentence":"Bilhvax is a recombinant vaccine targeting schistosome antigens to induce immune responses against Schistosoma haematobium infection.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:04:18.910Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schistosomiasis haematobium (urogenital schistosomiasis)"}]},"trialDetails":[{"nctId":"NCT00870649","phase":"PHASE3","title":"Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-02","conditions":"Urinary Schistosomiasis, Schistosoma Haematobium","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bilhvax vaccine (Sh28GST)","genericName":"Bilhvax vaccine (Sh28GST)","companyName":"Institut National de la Santé Et de la Recherche Médicale, France","companyId":"institut-national-de-la-sant-et-de-la-recherche-m-dicale-france","modality":"Biologic","firstApprovalDate":"","aiSummary":"Bilhvax is a recombinant vaccine targeting schistosome antigens to induce immune responses against Schistosoma haematobium infection. Used for Schistosomiasis haematobium (urogenital schistosomiasis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}